Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
CLEOCIN HYDROCHLORIDE vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin hydrochloride is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, thereby interfering with peptide bond formation and chain elongation.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
150-450 mg orally every 6 hours (oral capsules). Maximum dose: 1.8 g/day.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 to 3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8.5 hours. No significant change in renal impairment.
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10% of the active drug is excreted in urine as unchanged clindamycin; about 3.6% in feces; remainder is metabolized primarily in liver. Renal excretion accounts for ~10% of elimination, biliary/fecal route accounts for ~90% including metabolites.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category C
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic